WAYFINDER: Findings on Tezepelumab in Severe Asthma

In the WAYFINDER trial, tezepelumab markedly reduced maintenance oral corticosteroid use and exacerbations in patients with corticosteroid-dependent severe asthma, offering a clinically meaningful steroid-sparing option.

The finding extends beyond phenotype-targeted biologics by demonstrating a broader anti-inflammatory benefit that could expand eligibility for biologic therapy.

About 90% of participants reduced steroid use, and roughly half stopped oral corticosteroids, meeting the trial endpoint of oral corticosteroid reduction.

Roughly two-thirds of participants had cessation of asthma attacks and recorded improvements in chronic rhinosinusitis and patient-reported outcomes.